Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Immune Regulatory Endotypes Defined by TRIM-Dependent Ubiquitin Signaling and IFN-NF-κB Network Activity in Ankylosing Spondylitis.

International journal of molecular sciences·2026

Same author

Comprehensive Experimental and Computational Characterization of a Phenylacetamide-Based Molecule.

BioMed research international·2026

Same author

Upregulation of HIF1A /miR-210 and downregulation of miR-383 in EOPE, IUGR, and EOPE/IUGR: Integrative bioinformatics insights into miR-383 targets.

Placenta·2026

Same author

Reduced Subfatin levels are independently associated with proliferative diabetic retinopathy, unlike Chromogranin-A.

Journal of diabetes and metabolic disorders·2026

Same author

Evaluation of the Anticancer Effects of DODP on Gene Expression and Oxidative Stress in Gastric Cancer: An Integrated Docking, Bioinformatics, and Experimental Approach.

Life (Basel, Switzerland)·2026

Same author

ACE2 Polymorphisms and COVID-19 Severity: A Study on Their Relationship with Clinical Findings.

Genetic testing and molecular biomarkers·2026

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Microsomal epoxide hydrolase polymorphisms.

Hatice Pinarbasi¹, Yavuz Silig, Ergun Pinarbasi

¹Department of Biochemistry, Faculty of Medicine, Cumhuriyet University, 58140 Sivas, Turkey. hpinar2658@gmail.com.

Molecular Medicine Reports

|April 8, 2011

Summary

This study investigated genetic variations in microsomal epoxide hydrolase, an enzyme involved in carcinogen metabolism. Frequencies of key polymorphisms were determined in a Turkish population, providing insights into their distribution.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Enzymatic Synthesis of Epoxidized Metabolites of Docosahexaenoic, Eicosapentaenoic, and Arachidonic Acids

Enzymatic Synthesis of Epoxidized Metabolites of Docosahexaenoic, Eicosapentaenoic, and Arachidonic Acids

Published on: June 28, 2019

Related Experiment Videos

Last Updated: Jun 3, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Enzymatic Synthesis of Epoxidized Metabolites of Docosahexaenoic, Eicosapentaenoic, and Arachidonic Acids

Enzymatic Synthesis of Epoxidized Metabolites of Docosahexaenoic, Eicosapentaenoic, and Arachidonic Acids

Published on: June 28, 2019

Area of Science:

Pharmacogenomics
Molecular Toxicology
Human Genetics

Background:

Microsomal epoxide hydrolase (mEH) is crucial for metabolizing environmental toxins and carcinogens.
Genetic variations (polymorphisms) in the mEH gene can alter enzyme activity, influencing individual susceptibility to diseases.
Two common polymorphisms, Tyr113His (exon 3) and His139Arg (exon 4), affect mEH enzyme function and activity.

Purpose of the Study:

To determine the genotype frequencies of mEH exon 3 (Tyr113His) and exon 4 (His139Arg) polymorphisms in a Turkish population.
To provide population-specific data on these pharmacogenetically relevant mEH variants.

Main Methods:

Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) was employed.
Genotyping was performed on DNA samples from 625 unrelated, healthy Turkish individuals.

Main Results:

For mEH exon 3, observed genotype frequencies were Tyr113Tyr (54%), Tyr113His (38%), and His113His (8%).
For mEH exon 4, observed genotype frequencies were His139His (69%), His139Arg (29%), and Arg139Arg (2%).

Conclusions:

The study established baseline genotype frequencies for two significant mEH polymorphisms in the Turkish population.
These findings contribute to understanding the genetic landscape of carcinogen metabolism in this demographic and have implications for personalized medicine and risk assessment.